Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Reports Stock Option and RSU Grant

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs) on March 5, 2025.

Summary

• Dianne C. Whitfield, the Chief Human Resources Officer of Tarsus Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the grant of stock options and restricted stock units (RSUs) to Whitfield on March 5, 2025.
• Whitfield received options to purchase 30,628 shares of common stock at an exercise price of $44.54.
• These options vest 25% on March 5, 2026, and then 1/48th monthly for the following three years, contingent upon continuous service.
• Whitfield also received 20,089 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance from the Chief Human Resources Officer.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest an expectation of continued service and contribution from the executive.

Industry Context

Granting stock options and RSUs is a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. These grants align executive compensation with the company's long-term performance and shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded pharmaceutical companies.
• Companies like Alcon and Bausch + Lomb also utilize similar equity-based compensation plans to incentivize their leadership teams.
• The vesting schedules described are typical, with vesting periods ranging from three to four years to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of investment in leadership and the company's future.

Key Dates